| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
|
J Clin Oncol
|
1999
|
2.23
|
|
2
|
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
|
Cancer Res
|
2000
|
2.17
|
|
3
|
Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.
|
N Engl J Med
|
1993
|
1.45
|
|
4
|
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.
|
Clin Pharmacol Ther
|
1991
|
1.03
|
|
5
|
Clinical pharmacology of cancer chemotherapy in children.
|
Pediatr Clin North Am
|
1989
|
0.98
|
|
6
|
New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.
|
Ther Drug Monit
|
1998
|
0.96
|
|
7
|
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
|
J Clin Oncol
|
1999
|
0.96
|
|
8
|
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.
|
Clin Pharmacol Ther
|
1989
|
0.94
|
|
9
|
Phase I study of Doxil and vinorelbine in metastatic breast cancer.
|
Ann Oncol
|
1999
|
0.87
|
|
10
|
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
|
Cancer Res
|
2001
|
0.86
|
|
11
|
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.
|
Clin Pharmacokinet
|
1997
|
0.86
|
|
12
|
Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support.
|
Blood
|
1993
|
0.85
|
|
13
|
Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.
|
Cytokine
|
1995
|
0.84
|
|
14
|
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
|
Cancer Chemother Pharmacol
|
1998
|
0.84
|
|
15
|
Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer.
|
Am J Respir Crit Care Med
|
1998
|
0.83
|
|
16
|
Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
|
Int J Hyperthermia
|
2005
|
0.83
|
|
17
|
The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
|
Biol Blood Marrow Transplant
|
1997
|
0.82
|
|
18
|
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.
|
Cancer Chemother Pharmacol
|
1997
|
0.82
|
|
19
|
A standardized parenteral nutrition solution: prescribing, use, processing, and material cost implications.
|
Hosp Pharm
|
1986
|
0.80
|
|
20
|
Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.
|
Bone Marrow Transplant
|
1999
|
0.80
|
|
21
|
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
|
Cancer Chemother Pharmacol
|
1996
|
0.80
|
|
22
|
Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity.
|
Bone Marrow Transplant
|
1995
|
0.80
|
|
23
|
A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
|
Bone Marrow Transplant
|
1997
|
0.79
|
|
24
|
Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
|
J Clin Oncol
|
1991
|
0.79
|
|
25
|
Carboplatin pharmacokinetics in young children with brain tumors.
|
Cancer Chemother Pharmacol
|
1996
|
0.79
|
|
26
|
Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
|
Bone Marrow Transplant
|
1998
|
0.78
|
|
27
|
High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways.
|
Mol Pharmacol
|
1993
|
0.77
|
|
28
|
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
|
Eur J Haematol
|
1995
|
0.77
|
|
29
|
Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.
|
Am J Respir Crit Care Med
|
2000
|
0.77
|
|
30
|
Metabolic jeopardy with high-dose cyclophosphamide?--not so fast.
|
Clin Cancer Res
|
1999
|
0.75
|
|
31
|
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
|
Eur J Haematol
|
1995
|
0.75
|
|
32
|
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
|
Ann Oncol
|
2000
|
0.75
|
|
33
|
Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
|
J Pharmacol Exp Ther
|
1992
|
0.75
|
|
34
|
Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
|
Cancer Chemother Pharmacol
|
1997
|
0.75
|
|
35
|
Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.
|
Pharmacotherapy
|
1999
|
0.75
|
|
36
|
Role of cytokines in autologous bone marrow transplantation.
|
Hematol Oncol Clin North Am
|
1993
|
0.75
|
|
37
|
A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy.
|
Pharmacotherapy
|
1997
|
0.75
|
|
38
|
Artifactual hypoglycemia associated with hematopoietic cytokines.
|
Arch Pathol Lab Med
|
1995
|
0.75
|